Saturday 17 October 2026 Export PEN’s income statement to Excel — free account

Penumbra, Inc.

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024. In the quarter to June 2026, revenue grew 14.9%, EPS fell 24.8%, free cash flow grew 10.8% and total debt fell 9.90%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.

320.86 0.34 −0.11%

Follow PEN

Alert me

Market cap: $12.7B
P/E: 78.4×
Fwd P/E: 63.5×
Dividend yield: —
F-score: 8/9
Altman Z: 20.17
Beneish M: −2.48
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.08

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	5	4	2	—	1	1	—	—	—	—	—	—

Insider Ownership 2.78%

Capital & Financial Ratios $m

Market Cap 12,650.00

Revenue 1,504.87

Net Income 160.59

Free Cash Flow 215.91

Net Debt (639.17)

Current Ratio 5.75

Debt/Equity 0.01

P/E ratio 78.45

Fwd P/E 63.50

P/S ratio 8.39

P/B ratio 8.25

Past 5Y EPS Growth —

This Y EPS Growth 23.75%

Next Y EPS Growth 26.06%

Next Y revenue growth 13.49%

Next 5Y EPS Growth 22.07%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 14.85%

10-year low 10-year high

P/S against its own 10 years 26.13%

10-year low 10-year high

P/B against its own 10 years 36.31%

10-year low 10-year high

EV/Sales against its own 10 years 25.47%

10-year low 10-year high

EV/FCF against its own 10 years 5.89%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	289	340	545	659
Receivables	202	168	190	190
Inventory	388	407	432	443
Other	—	—	—	—
	915	951	1,217	1,344

	2023	2024	2025	Q'26
Payables	27	31	35	45
ST’ Debt	—	—	—	—
Other	—	—	—	—
	151	158	183	234

Compound Annual Growth %

	10y	5y	3y
Sales	22.39%	20.16%	18.33%
Cash Flow	0.00%	0.00%	0.00%
Earnings	66.52%	0.00%	0.00%
Book Value	19.90%	17.49%	12.64%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	375	390	—	—	—
’25	324	339	355	385	1,404
’24	279	299	301	316	1,195
’23	241	261	271	285	1,059
’22	204	208	214	221	847
’21	169	184	190	204	748
’20	137	105	151	167	560

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	87	46	—	—	—
’25	49	45	58	86	239
’24	38	23	56	51	168
’23	13	17	31	36	97
’22	(5)	(40)	(13)	1	(56)
’21	(14)	(3)	36	(9)	10
’20	(6)	(22)	(4)	(2)	(33)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	73	33	—	—	—
’25	36	29	42	68	175
’24	32	18	51	46	147
’23	9	13	26	33	81
’22	(9)	(44)	(19)	(2)	(75)
’21	(18)	(7)	31	(17)	(12)
’20	(16)	(28)	(8)	(6)	(58)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.82	0.88	—	—	—
’25	1.00	1.15	1.17	1.20	4.52
’24	0.28	(1.55)	0.75	0.86	0.36
’23	0.22	0.48	0.23	1.38	2.32
’22	0.00	(0.10)	(0.06)	0.10	(0.05)
’21	0.32	0.25	0.24	(0.66)	0.14
’20	0.04	(0.34)	(0.24)	0.10	(0.44)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	40.23	63.05	82.55	115.55	121.80	171.56	114.87	180.93	148.00	221.26	Analyst estimates 2026–2028 Powerpack
	High	79.49	116.35	167.35	185.70	277.00	320.00	287.53	348.67	277.34	321.38
People
People	Employees	1,500	1,700	2,200	2,700	3,300	3,800	3,900	4,200	4,500	4,700
	Revenue/emp, $m	0.18	0.20	0.20	0.20	0.17	0.20	0.22	0.25	0.27	0.30
Income, $m
Income, $m	Revenue	263	334	445	547	560	748	847	1,059	1,195	1,404
	Gross margin, %	64.88	65.06	65.75	67.95	60.34	63.59	63.18	64.49	63.20	67.14
	EBT	(1)	2	2	50	(38)	(11)	4	80	21	205
	EBT margin, %	(0.33)	0.74	0.36	9.16	(6.78)	(1.40)	0.46	7.52	1.75	14.61
	Net income	15	5	3	47	(19)	3	(2)	91	14	178
	Depreciation	3	4	6	8	15	16	24	27	24	17
Per share, $
Per share, $	Revenue	8.64	10.12	13.03	15.75	15.67	20.33	22.39	27.57	30.92	36.07
	Earnings	0.49	0.14	0.19	1.39	(0.44)	0.14	(0.05)	2.37	0.36	4.57
	Cash flow	(0.42)	0.38	0.84	0.77	(0.93)	0.26	(1.47)	2.53	4.36	6.13
	Capex	(0.45)	(0.46)	(0.28)	(0.64)	(0.69)	(0.58)	(0.51)	(0.42)	(0.55)	(1.64)
	Free cash flow	(0.87)	(0.07)	0.56	0.13	(1.62)	(0.32)	(1.98)	2.11	3.81	4.49
	Book value	8.75	12.14	12.37	13.97	17.83	25.95	26.40	30.70	29.79	36.68
	Shares, m	30	33	34	35	36	37	38	38	39	39
Valuation, ×
Valuation, ×	P/E	132.03	710.86	643.16	117.34	0.00	1,915.47	0.00	104.16	641.84	68.03
	P/S	7.41	8.93	9.38	10.43	11.17	14.13	9.88	8.88	7.68	8.62
	P/B	7.32	7.44	9.88	11.76	9.81	11.07	8.38	7.97	7.97	8.48
	EV/Sales	6.92	8.28	8.92	10.13	10.74	13.82	9.69	8.63	7.41	8.25
	EV/FCF	(68.93)	17,389.76	206.76	1,220.75	(103.82)	(884.97)	(109.49)	112.58	60.13	66.17
Cash, $m
Cash, $m	Operating cash flow	(13)	13	29	27	(33)	10	(56)	97	168	239
	Capex	(14)	(15)	(10)	(22)	(25)	(21)	(19)	(16)	(21)	(64)
	Free cash flow	(26)	(2)	19	5	(58)	(12)	(75)	81	147	175
Balance, $m
Balance, $m	Working capital	228	331	345	372	512	558	611	764	793	1,034
	Total debt	—	—	—	27	27	27	25	24	22	21
	Net debt	(129)	(215)	(201)	(163)	(238)	(228)	(163)	(266)	(318)	(524)
	Shareholders’ equity	267	400	422	486	638	954	999	1,179	1,151	1,428
Returns, %
Returns, %	ROA	5.18	1.19	1.33	8.21	(2.11)	0.51	(0.15)	6.21	0.91	10.58
	ROIC	(0.61)	0.39	(0.24)	9.19	(6.08)	(0.65)	0.45	5.03	0.70	13.09
	ROE	5.94	1.40	1.60	10.67	(2.80)	0.66	(0.21)	8.35	1.20	13.78

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ZBH Zimmer Biomet Holdings, Inc.	$18.0B	23.0×	17.7×	+4.80% (above 0%: growing)	+33.77% (above 0%: growing)	+13.05% (above 0%: growing)	70.81%	14.98%	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%	Compare
GMED Globus Medical, Inc.	$10.6B	19.3×	20.3×	+5.94% (above 0%: growing)	−25.33% (below 0%: shrinking)	+571.30% (above 0%: growing)	69.42%	23.10%	Compare
BIO.B Bio-Rad Laboratories, Inc.	$10.3B	43.7×	—	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
GKOS Glaukos Corporation	$9.8B	— (loss-making)	— (loss-making)	+49.54% (above 0%: growing)	n/m	+211.83% (above 0%: growing)	81.67%	(9.30%)	Compare
BIO Bio-Rad Laboratories, Inc.	$9.8B	42.5×	35.4×	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
PODD Insulet Corporation	$9.6B	26.4×	24.7×	+23.51% (above 0%: growing)	+328.13% (above 0%: growing)	−70.51% (below 0%: shrinking)	70.18%	16.18%	Compare
BRKR Bruker Corporation	$8.6B	— (loss-making)	55.7×	+5.15% (above 0%: growing)	n/m	+28.63% (above 0%: growing)	49.61%	(7.79%)	Compare
Median of peers	$10.0B	30.9×	22.5×	+5.55%	+19.02%	+20.84%	69.42%	11.15%

All 149 Medical Devices stocks →

Penumbra, Inc. (PEN) key facts

Strength: Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
Penumbra, Inc. (PEN) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, PEN traded at $320.86, a market capitalization of $12.7 billion.
Return on equity was 13.8% and debt-to-equity 0.01.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 20.17 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.